Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

NCT00737282 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

175

Enrollment

INDUSTRY

Sponsor class

Stopped Repros stopped study for safety and FDA put study on hold.

Conditions

Uterine Fibroids

Interventions

DRUG: Proellex 25 mg
DRUG: Proellex 50 mg

Sponsor

Repros Therapeutics Inc.